AAP
VIVO

Ardsley Advisory Partners’s Meridian Bioscience Inc VIVO Stock Holding History

Ardsley Advisory Partners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-23,500
Closed -$547K – 190
2020
Q2 		$547K Buy
+23,500
New +$341K 0.12% 82
2015
Q3 		– Sell
-10,000
Closed -$186K – 197
2015
Q2 		$186K Sell
10,000
-5,000
-33% -$92.7K 0.02% 150
2015
Q1 		$286K Buy
+15,000
New +$277K 0.04% 154

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ardsley Advisory Partners's VIVO Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Meridian Bioscience Inc (VIVO) in Q3 2020, closing a stake of 23,500 shares — an estimated $547K sold.

Ardsley Advisory Partners first reported a position in VIVO in Q1 2015 and held it in 3 quarters. The position peaked at $547K in Q2 2020. 191 funds tracked by Wall St. Rank hold VIVO as of Q3 2020.

  • Ardsley Advisory Partners reported no remaining Meridian Bioscience Inc position as of Q3 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 23,500 Meridian Bioscience Inc shares in Q3 2020, an estimated $547K.
  • Ardsley Advisory Partners first reported a position in Meridian Bioscience Inc in Q1 2015 and held it in 3 quarters.
  • Ardsley Advisory Partners's Meridian Bioscience Inc position peaked at $547K in Q2 2020.
  • 191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.